Global Biological Drugs Market: Snapshot
The global market for biological drugs
has been demonstrating an upward movement since the last few years. The
rising concerns over the increasing cases of side-effects caused by
conventional medicines and drugs are having a positive impact on the
demand for biological drugs across the world. The trend is expected to
remain so over the forthcoming years with the opportunity in the
worldwide biological drugs market expanding at a CAGR of 10.10% during
the period from 2014 to 2020 and reaching US 287.1 bn by the end of the
forecast period.
Demand for Enbrel to Remain Strong in Future
Lantus, epogen, avonex, victoza, levemir,
betaseron, enbrel, humalog, aranesp, neulasta, novolog, neupogen,
rebif, and eylea are some of the main therapeutic proteins used in
biological drugs. Enbrel has been witnessing a greater demand than other
therapeutic proteins, worldwide. Enbrel is used in the treatment of
auto-immune diseases, such as juvenile rheumatoid arthritis, plaque,
psoriatic, and psoriasis. The growing prevalence of these diseases has
influenced the sales of enbrel.
Analysts expect the segment to rise at a
CAGR of 14.50% over the forecast period. However, the concerns over
side-effects of this protein, such as multiple sclerosis, tuberculosis,
allergic reactions, and blood related infections, may limit its demand
to some extent in the years to come. Lantus and neulasta are the other
important therapeutic proteins, which are likely to gain impetus in the
global market over the next few years.
Increasing Investments for Research and Development in Biological Drugs to Ensure North America’s Leadership
The global market for biological drugs is
spread across Europe, North America, Asia Pacific, and the Rest of the
World. Thanks to the increased application of biological drugs for the
treatment of a number of diseases, such as diabetes, cancer, and other
chronic medical conditions, North America has emerged as the leading
consumer of biological drugs. Over the forthcoming years, investments to
increase research and development activities in biological drugs is
likely to heighten, which consequently, is expected to boost the North
America biological drugs to a great extent. Expanding at a CAGR of
10.90%, this region will continue to hold the leadership in the global
market for biological drugs during the forecast period.
Europe and Asia Pacific are also projected to gain substantial momentum in their respective markets for biological drugs in the coming years, thanks to the growing awareness among consumers pertaining to the efficiency and other benefits of biological drugs. The unmet medical needs in Asia Pacific is also anticipated to add significantly to the growth of the global biological drugs market in the near future.
Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1694
GlaxoSmithKline Plc., Biogen Idec,
Novartis AG, Baxter International Inc., Amgen Inc., Merck & Co.
Inc., Bristol-Myers Squibb Co., Eli Lilly and Co., Pfizer Inc. and
Abbott Laboratories are some of the leading manufacturers of biological
drugs across the world.
No comments:
Post a Comment